"Ambroxol" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
A metabolite of BROMHEXINE that stimulates mucociliary action and clears the air passages in the respiratory tract. It is usually administered as the hydrochloride.
| Descriptor ID |
D000551
|
| MeSH Number(s) |
D02.092.146.271.100 D02.092.384.175.100
|
| Concept/Terms |
Ambroxol- Ambroxol
- 4-(((2-Amino-3,5-dibromophenyl)methyl)amino)cyclohexanol
- Bromhexine Metabolite VIII
- Metabolite VIII, Bromhexine
Lasolvan- Lasolvan
- Surbronc
- Sekretovit
- Mucosolvan
Pulmonal S- Pulmonal S
- Ringelheimer Pulmonal
- Pulmonal, Ringelheimer
|
Below are MeSH descriptors whose meaning is more general than "Ambroxol".
Below are MeSH descriptors whose meaning is more specific than "Ambroxol".
This graph shows the total number of publications written about "Ambroxol" by people in this website by year, and whether "Ambroxol" was a major or minor topic of these publications.
To see the data from this visualization as text,
click here.
| Year | Major Topic | Minor Topic | Total |
|---|
| 2015 | 0 | 1 | 1 |
| 2017 | 0 | 1 | 1 |
| 2018 | 2 | 0 | 2 |
| 2020 | 0 | 1 | 1 |
| 2021 | 1 | 2 | 3 |
To return to the timeline, click here.
Below are the most recent publications written about "Ambroxol" by people in Profiles.
-
Interventions for the treatment of persistent post-COVID-19 olfactory dysfunction. Cochrane Database Syst Rev. 2021 07 22; 7:CD013876.
-
Inhibition of acid sphingomyelinase by ambroxol prevents SARS-CoV-2 entry into epithelial cells. J Biol Chem. 2021 Jan-Jun; 296:100701.
-
SARS-CoV-2 and SARS-CoV Spike-Mediated Cell-Cell Fusion Differ in Their Requirements for Receptor Expression and Proteolytic Activation. J Virol. 2021 04 12; 95(9).
-
Value of chest imaging in the newborn with suspected COVID-19. Eur Rev Med Pharmacol Sci. 2020 11; 24(22):11971-11976.
-
Azithromycin and ambroxol as potential pharmacotherapy for SARS-CoV-2. Int J Antimicrob Agents. 2020 Dec; 56(6):106192.
-
First case of focal epilepsy associated with SARS-coronavirus-2. J Med Virol. 2020 10; 92(10):2238-2242.
-
Pulmonary surfactant itself must be a strong defender against SARS-CoV-2. Med Hypotheses. 2020 Nov; 144:110020.
-
Safety of ambroxol in the treatment of airway diseases in adult patients. Expert Opin Drug Saf. 2018 Dec; 17(12):1211-1224.
-
Investigation of a potential drug-drug interaction between salbutamol and ambroxol and bioequivalence of a new fixed-dose combination containing these two drugs in healthy Chinese subjects. Int J Clin Pharmacol Ther. 2018 May; 56(5):247-254.
-
Impact of Mucolytic Agents on COPD Exacerbations: A Pair-wise and Network Meta-analysis. COPD. 2017 Oct; 14(5):552-563.